Recent advancements in uropathology are significantly impacting the diagnosis, classification, and potentially the treatment of urological cancers. The integration of molecular pathology and cancer genetics is leading to more precise and personalized approaches, as reflected in the updated 5th edition WHO Classification of Urinary and Male Genital Tumours (2022). Biomarkers, particularly those found in urine, continue to be a crucial area of research for non-invasive detection and monitoring of bladder cancer, although current FDA-approved markers have limitations in sensitivity and specificity. Artificial intelligence is emerging as a promising tool in uropathology, with applications in diagnosis, prognosis, and potentially guiding treatment decisions across various urological malignancies, including bladder, prostate, and renal cell cancers.
Key Themes and Important Ideas/Facts:
1. The Evolving Landscape of Uropathology with Molecular and Genetic Integration:
* The field of uropathology is moving beyond purely morphology-based diagnosis to an integrated approach incorporating clinical, histologic, immunohistochemical, cytogenetic, and molecular findings. This is particularly evident in the 2022 WHO classification. (Source 5)
* Molecular tests are becoming increasingly important for accurate classification, especially in cases with difficult-to-classify or undifferentiated features. (Source 5)
* The 2022 WHO classification of renal tumors introduces a "molecularly defined renal tumor classification" alongside established morphologically defined entities. (Source 5)
* Molecular testing is essential for the diagnosis of certain newly defined entities like ELOC-mutated RCC. (Source 5)
* Genetic alterations are being standardized as "variants," distinct morphologies as "histologic patterns," and unique morphologies with prognostic significance as tumor "subtypes" in the context of invasive urothelial carcinoma. (Source 6, 7)
2. Biomarkers in Bladder Cancer Diagnosis and Monitoring:
* Biomarkers in bladder cancer play a crucial role in early detection, prognosis, and treatment. (Source 2)
* FDA-approved molecular biomarkers like BTA stat, BTA TRAK, and NMP22, derived from urinary samples, are useful for diagnosis and monitoring. However, they are "seriously challenged in the detection of early bladder cancer due to their limited sensitivity and specificity." (Source 2)
* Sensitivities for these approved markers vary widely (e.g., BTA stat 40-72%, BTA TRAK 70%, NMP22 11-85.7%), and specificities also show considerable variation (e.g., BTA stat 29-96%, BTA TRAK 80%, NMP22 77-100%). These variations highlight the need for improved diagnostic systems. (Source 2)
* False positives can occur with BTA and NMP22 tests due to factors like hematuria, inflammation, and recent instrumentation, reducing their specificity. (Source 2)
* Current FDA-approved biomarkers "cannot substitute cystoscopy and should not be considered a routine part of surveillance after TUR in superficial bladder cancer patients." (Source 2)
* Research into novel biomarkers is ongoing, including extracellular vesicles (EVs) and exosomes, UBC® Rapid test, XPERT BC Monitor, BC UroMark, and various protein, cellular, metabolic, immunological, and genetic markers. (Source 2)
* Urine biomarkers are attractive due to their minimally invasive nature for early-stage detection. (Source 2)
* MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are being investigated as potential bladder cancer biomarkers. Several miRNAs are reported to be overexpressed in bladder cancer tissues, suggesting diagnostic or predictive value (e.g., miR-20a, miR-155, miR-21, miR-133b, miR-15b). (Source 2)
* Some tumor tissue biomarkers, such as EGFR and PDGFRA gene expression, can provide information about cancer aggressiveness and potential for recurrence. (Source 2)
* New portable devices and panels of urinary biomarkers are being developed, such as the Xpert® Bladder Cancer Monitor and BC UroMark, but they also have limitations in sensitivity and specificity and cannot replace cystoscopy for definitive diagnosis. (Source 2)
* Sensitivity and specificity are key measures for evaluating diagnostic tests, and their values for existing bladder cancer detection methods vary significantly. For instance, urine microscopy has higher specificity (92-96%) than sensitivity (87-91%), while urine cytology has a lower sensitivity (13.3-86%) but higher specificity (73-100%). Urine markers show a wide range of sensitivity and specificity depending on the specific marker and population. (Source 2)
* Challenges remain in the biomarker field, including the need for standardized testing procedures and validation in clinical settings, as well as data integration challenges with multi-omics approaches. (Source 2)
* Clinical trials are evaluating new urinary biomarkers like the ADXBLADDER test (detecting MCM5), UroSEEK (targeting multiple genes), and CxBladder (measuring specific mRNAs), which show promising sensitivity but often have lower specificity compared to conventional techniques. (Source 2)
3. Updates in the WHO Classification (5th Edition, 2022):
* The 5th edition WHO Classification of Urinary and Male Genital Tumours (2022) includes significant changes in the classification and diagnosis of urological tumors, particularly renal tumors. (Source 6, 7)
* In bladder cancer:
* Inverted urothelial papilloma is reserved for almost exclusively inverted lesions. (Source 6, 7)
* Papillary urothelial hyperplasia and urothelial proliferation with undetermined malignant potential are now considered "early low-grade non-invasive papillary carcinoma." (Source 6, 7)
* New criteria for reporting papillary tumors address grade heterogeneity: tumors with ≥ 5% high-grade component are diagnosed as "high-grade," while those with < 5% high-grade component are diagnosed as "low-grade with < 5% high-grade component." (Source 6, 7)
* Urothelial dysplasia is still used as a diagnostic term for lesions below carcinoma in situ, although reproducible criteria are lacking. (Source 6, 7)
* TERT promoter mutations can help distinguish urothelial carcinoma from non-neoplastic processes and establish urothelial origin. (Source 6, 7)
* Specific genetic alterations (FGFR3, ERCC2, DNA damage repair genes) may predict response to targeted therapies and chemotherapy in invasive urothelial carcinoma. (Source 6, 7)
* Predictors of response to immune checkpoint inhibitors include PDL1 expression, tumor mutation burden, and microsatellite instability/mismatch repair defect status. (Source 6, 7)
* Muscle-invasive bladder carcinoma is divided into six molecular subgroups with different prognoses. (Source 6, 7)
* In renal cell carcinoma (RCC):
* The classification integrates clinical, histologic, immunohistochemical, cytogenetic, and molecular findings. (Source 5)
* A new family of molecularly defined RCCs is introduced (Table 1 in Source 5). (Source 5)
* Pathological diagnosis of morphologically defined RCCs typically involves histologic examination and immunohistochemistry (IHC), with subtype-specific genetic alterations as ancillary tests. (Source 5)
* Key features for diagnosing common morphologically defined RCCs are described, including Clear Cell RCC (VHL inactivation, CA9 IHC), Papillary RCC (gains of chromosomes 7 and 17, loss of Y chromosome, MET mutation, AMACR IHC; Type 1 and 2 distinction is eliminated), Chromophobe RCC (losses of multiple chromosomes, CK7 IHC), and Eosinophilic Solid and Cystic RCC (TSC1/TSC2 inactivation, CK20 IHC). (Source 5)
* Several emerging/provisional entities are included under Papillary RCC, with specific molecular alterations. (Source 5)
* The oncocytic renal tumor category includes oncocytoma and Chromophobe RCC, with provisional entities like low-grade oncocytic renal tumor and eosinophilic vacuolated tumor associated with TSC1/2 or MTOR mutations. (Source 5)
* Molecularly defined RCCs often have diverse histology but are characterized by specific molecular alterations, ideally confirmed by FISH or NGS, though IHC can often be diagnostic. (Source 5)
* Detailed characteristics of key molecularly defined RCCs are provided: TFE3-Rearranged RCC (TFE3 fusions, nuclear TFE3 IHC), TFEB-Altered RCC (TFEB fusion/amplification, nuclear TFEB IHC), ELOC-Mutated RCC (ELOC biallelic inactivation, CK7 IHC, requires molecular testing), FH-Deficient RCC (FH biallelic mutation/inactivation, FH immunonegativity/2SC immunopositivity), SDH-Deficient RCC (SDH biallelic inactivation, SDHB negativity), ALK-Rearranged RCC (ALK fusion, ALK IHC), and SMARCB1-Deficient Medullary Carcinoma (SMARCB1 loss/inactivation, SMARCB1 negativity). (Source 5)
* The 2022 WHO classification aims to provide more precise prognostic insights for appropriate management. (Source 5)
* In testicular tumors:
* Gonadoblastoma is moved to the "noninvasive germ cell neoplasia" category. (Source 6, 7)
* Teratoma is considered to have a somatic-type malignancy if the component resembling a neoplasm has an overgrowth of at least a 5 mm focus. (Source 6, 7)
* Somatic malignancy composed of immature neuroectoderm is renamed "teratoma with embryonic-type neuroectodermal tumor." (Source 6, 7)
* Well-differentiated neuroendocrine tumor is renamed "testicular neuroendocrine tumor, prepubertal-type." (Source 6, 7)
* The Leydig cell tumor Scaled Score (LeSS) is mentioned but requires further validation. Leydig cell tumors can be FH deficient, potentially warranting testing in high-risk cases. (Source 6, 7)
* Sertoliform cystadenoma of the rete testis is now part of Sertoli cell tumor. (Source 6, 7)
* The signet ring pattern of Sertoli cell tumor is a separate tumor called "signet ring stromal tumor," characterized by signet ring cells lacking mucin and specific immunostaining. (Source 6, 7)
* Myoid gonadal stromal tumor is confirmed as a distinct entity. (Source 6, 7)
* Well-differentiated papillary mesothelioma is renamed "well-differentiated papillary mesothelial tumor." (Source 6, 7)
* In penile tumors:
* Terminology for squamous cell carcinoma groupings is changed to HPV-independent and HPV-associated. (Source 6, 7)
* Several previously distinct subtypes are removed and are now considered patterns within usual type squamous cell carcinoma (pseudohyperplastic, pseudoglandular) or verrucous carcinoma (carcinoma cuniculatum). (Source 6, 7)
4. The Role of Artificial Intelligence in Uropathology:
* Artificial intelligence (AI) is being explored for applications in uropathology. (Source 1)
* Potential uses of AI in uropathology include diagnosis and prognosis of bladder cancer, prostate cancer, and renal cell cancer. (Source 1)
* The keywords of the review article on AI in Uropathology explicitly list these cancers as areas of focus. (Source 1)
* While the provided excerpts from this source are limited to the title, authors, affiliations, and keywords, the publication type is listed as a "Review," indicating a summary of existing research on the topic. (Source 1)
5. Bladder Cancer Pathogenesis and Conventional Detection Methods:
* Bladder cancer is characterized by rapid cell growth in the bladder. (Source 2)
* The bladder is a muscular organ that stores and expels urine. (Source 2)
* The kidneys work with the bladder to eliminate waste. (Source 2)
* Specific mutations, such as in the H-Ras protein (particularly G12V), are associated with bladder carcinoma, leading to continuously active Ras proteins that are essential for cancer cell survival and division. (Source 2)
* Molecular analysis of H-Ras is implicated in the initial stages of bladder cancer and is mainly associated with benign tumors, though rare transformations to higher malignancy stages occur. (Source 2)
* A single nucleotide polymorphism (81T>C) has been correlated with significantly increased odds of developing advanced and more malignant bladder carcinomas. (Source 2)
* RAS gene mutations augment bladder cancer through the Ras-RAF-MEK-ERK signaling pathway, leading to cell proliferation. Understanding these mechanisms is crucial for targeted therapies. (Source 2)
* Conventional detection methods include comprehensive discussions with healthcare providers, physical examinations, urinalysis, urine culture, cystoscopy (with potential biopsy), urinary cytopathology, and imaging techniques like CT scans and ultrasounds. (Source 2)
* Biomarkers are chemicals in the human system that can signal disease and are found in body fluids and tissues, including proteins, nucleic acids, or cells that provide information about cancer presence. (Source 2)
* The Bladder Tumor Antigen (BTA) STAT, BTA TRAK, and Nuclear Matrix Protein 22 (NMP22) tests are major biomarkers used, relying on detecting complement factor H-related protein in urine. (Source 2)
* BTA STAT is a rapid point-of-care immunochromatographic assay, while BTA TRAK is a quantitative ELISA measurement. Both are FDA-approved for surveillance alongside cystoscopy. (Source 2)
* NMP22 is released into urine as bladder cancer progresses and is used for detection and recurrence after TUR. (Source 2)
* Commonly recognized groups of biomarkers in bladder cancer include protein, cellular, metabolic, immunological, and genetic biomarkers. (Source 2)
* Pan-cancer biomarkers are being identified through large-scale genomics data and computational approaches, aiming to reveal similarities and dissimilarities across different cancers and potentially enhance early detection and stratification. (Source 2)
* Biomarkers can be found in tissue (Immunohistochemistry, Cytology, Molecular Classification) and various body fluids besides blood and urine, such as extracellular vesicles, plasma membrane proteins, surfactant protein D, cell-free DNA, and viral load. (Source 2)
* Urine biomarkers, like Nucleic Acid Testing, Protein Testing, and Whole Genome Sequencing, are widely studied due to their minimal invasiveness. Potential urine biomarkers include BLCA-4 NMP, hyaluronic acid, and exosomes. (Source 2)
* Studies comparing urine-based molecular diagnostics (NMP22, BTA stat, BTA TRAK) and blood-based markers (CEA, CYFRA21-1) show moderate sensitivity and specificity for both, with urine tests being slightly superior in differentiating NMIBC and for high-risk populations. (Source 2)
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit depositologico.substack.com